PDCD1 and classic Hodgkin lymphoma: This study supported the superiority of pembrolizumab (anti-PD-1 therapy) over BV in r/r cHL; however, there are still few long-term, relapse-free survivors in either treatment group, so most patients will eventually be treated with both agents at some time in the course of therapy for r/r cHL.